Launch Conditionality: What’s at stake?

The increasing importance of Real World Evidence (RWE) and the need for a multi-stakeholder approach

What is Needed to Reinforce Biopharmaceutical Innovation in Europe?

The European Health Data Space (EHDS): How will it impact health technology companies operating in or about to enter the EU?

From the EUCOPE Blog archives

GUEST: What’s on the horizon for life sciences and health care?

June 30, 2022

Five Priorities for a Successful EU HTA Procedure

April 27, 2022

HERA: closer coordination in the EU against COVID-19

February 26, 2021

Is it Time for a new Health Paradigm in the EU?

November 20, 2020

Harnessing Europe’s untapped potential: small and medium pharma

June 2, 2020

To the archives